Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01659827
Recruitment Status : Completed
First Posted : August 8, 2012
Last Update Posted : December 11, 2013
Information provided by (Responsible Party):
MiMedx Group, Inc.

August 2, 2012
August 8, 2012
December 11, 2013
September 2012
March 2013   (Final data collection date for primary outcome measure)
Change from Baseline in American Orthopaedic Foot and Ankle Society (AOFAS) Hind Foot Score at 8 Weeks [ Time Frame: 8 Weeks ]
Same as current
Complete list of historical versions of study NCT01659827 on Archive Site
  • Time to return to normal activities [ Time Frame: Up to 8 Weeks ]
  • Pain scale [ Time Frame: Weekly up to 8 Weeks ]
Same as current
Not Provided
Not Provided
Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis
A Prospective, Randomized, Blinded, Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis
The purpose of this study is to determine whether the AmnioFix Injectable human amniotic membrane is effective in the treatment of recalcitrant plantar fasciitis.
Not Provided
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Plantar Fasciitis
  • Other: Marcaine
    Injection of 2cc of Marcaine
  • Other: 0.5cc AmnioFix
    Injection of 0.5cc of AmnioFix Injectable
  • Other: 1.25cc AmnioFix
    Injection of 1.25cc of AmnioFix Injectable
  • Other: Saline
    Injection of 1.25cc of Saline
  • Sham Comparator: Control
    Initial injections of Marcaine and Saline (one each)
    • Other: Marcaine
    • Other: Saline
  • Experimental: 0.5cc AmnioFix Injectable
    Initial injections of Marcaine and 0.5cc AmnioFix (one each)
    • Other: Marcaine
    • Other: 0.5cc AmnioFix
  • Experimental: 1.25cc AmnioFix Injectable
    Initial injections of Marcaine and 1.25cc AmnioFix (one each)
    • Other: Marcaine
    • Other: 1.25cc AmnioFix
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 2013
March 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. At least 18 years old.
  2. Both male and female patients will be selected.
  3. Plantar fasciitis has been treated with conservative usual care for at least 8 weeks, including at least three of the following modalities

    1. RICE
    2. Corticosteroid injection
    3. Stretching exercises
    4. NSAIDs
    5. Orthotics
  4. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  5. Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
  6. Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.

Exclusion Criteria:

  1. Prior surgery at the site
  2. Site that exhibits clinical signs and symptoms of infection
  3. History of chronic plantar fasciitis of more than twelve months
  4. Evidence of significant neurological disease of the feet
  5. Non Ambulatory Patients
  6. The presence of comorbidities that can be confused with or can exacerbate the condition including:

    • Calcaneal stress fracture
    • Nerve entrapment syndrome (baxter nerve syndrome or tarsal tunnel)
    • Plantar fascial rupture
    • Systemic disorders associated with enthesiopathy such as Gout, Reiters syndrome, rheumatoid arthritis, etc.
    • Achilles tendonitis
    • Fat pad atrophy
    • Fibromyalgia
  7. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  8. Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding Screening.
  9. History of radiation at the site.
  10. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  11. Study foot has been previously treated with tissue engineered materials such as PRP within the last 30 days.
  12. Patients who are unable to understand the aims and objectives of the trial.
  13. Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  14. Pregnant or breast feeding. No pregnancy within the past 6 months.
  15. Allergy to Gentamycin Streptomycin
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
MiMedx Group, Inc.
MiMedx Group, Inc.
Not Provided
Principal Investigator: Charles M. Zelen, DPM Professional Education and Research Institute
MiMedx Group, Inc.
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP